Navigation Links
Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex
Date:5/30/2008

Isolagen Intends to Appeal Action

EXTON, Pa., May 30 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) today announced that on May 29, 2008 it received notice from the staff of the American Stock Exchange (AMEX) indicating that, in the staff's opinion, the Company's plan of compliance did not demonstrate its ability to regain compliance with the Exchange's continued listing standards set forth in Sections 1003 (a)(i)-(iii) of the AMEX Company Guide within the prescribed time period, and, therefore, that its common stock is subject to being delisted from the Exchange. As discussed in the Company's Form 8-K dated March 14, 2008 and in Item 1A. of the Company's Form 10-Q for the quarter ended March 31, 2008, the Company had initially received a non-compliance notice from the staff of the AMEX on March 12, 2008, and had submitted a plan of compliance to the AMEX on April 14, 2008.

Isolagen intends to appeal this determination and will request a hearing before a committee of the Exchange. There can be no assurance that the Company's request for continued listing will be granted after such hearing.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit http://www.isolagen.com.

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release, include, without limitation, that the Company's request for continued listing with AMEX will be granted. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward- looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as well as other public filings with the SEC since such date


'/>"/>
SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Isolagen, Inc. Sells Switzerland Facility
2. Isolagen, Inc. Promotes Todd Greenspan to Chief Financial Officer (CFO)
3. Isolagen, Inc. Receives Notification Letter from American Stock Exchange
4. Isolagen, Inc. Postpones Annual Meeting
5. Chem Rx Corporation Reports First Quarter 2008 Financial Results
6. CRH Medical reports Q1 2008 results
7. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
8. Unilens Vision Reports Increased Royalty Income
9. China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008
10. Shamir Optical Industry Ltd. Reports First Quarter 2008 Results
11. Nyer Medical Group, Inc. Reports Revenues of $18.9 Million With Net Loss of $.16 Per Share for 3rd Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... It's ... there are a number of illnesses that are unclear as to whether or not ... their heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look into ...
(Date:4/28/2017)... ... ... affects much more than energy – it also has mental and physical benefits. According to ... time, which can increase the risk of having a car accident. , This week ... to help you sleep better and feel better:, , Turn off ...
(Date:4/28/2017)... ... , ... The Radiology Business Management Association (RBMA) is pleased to ... election process has been in place since the RBMA was founded in 1968 with ... succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... America (UCAOA) and College of Urgent Care Medicine will host industry leaders for ... and speakers will help those in the industry adapt to the issues currently ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... Creator responds to and which He does not. Yisrayl says with so many titles ... the true name, but he says with a little Scripture, backed with a lot of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... EAST HANOVER, N.J. , April 19, 2017 ... study conducted by the National Heart, Lung, and ... Health (NIH) demonstrating that 58% of patients with ... at six months when treated with eltrombopag at ... treatment 1 . The study evaluated three sequential ...
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
(Date:4/18/2017)... Viverae ® , a leader in workplace ... IBM ® Watson Campaign Automation, implementing behavioral messaging ... a personalized experience. Through digital engagement, the platform prompts ... real time. The enhanced experience drives engagement by focusing ... they are in their journey to health. ...
Breaking Medicine Technology: